NCT06005402View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of CSX-1004

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

May 28, 2024

Study Completion Date

May 28, 2024

Conditions
Opioid OverdoseOpioid Use Disorder
Interventions
BIOLOGICAL

CSX-1004

Recombinant human immunoglobulin G (IgG) 1λ monoclonal antibody specific for fentanyl and structurally related fentanyl analogs

BIOLOGICAL

Placebo

Sterile saline for injection

Trial Locations (1)

66212

Dr. Vince Clinical Research, Overland Park

Sponsors
All Listed Sponsors
collaborator

Dr. Vince Clinical Research

OTHER

lead

Cessation Therapeutics, Inc.

INDUSTRY

NCT06005402 - Safety, Tolerability, and Pharmacokinetics of CSX-1004 | Biotech Hunter | Biotech Hunter